Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin

Area of Science:

• Endocrinology
• Immunology
• Clinical Diagnostics

Background:

• Graves' disease is an autoimmune disorder causing hyperthyroidism.
• Thyroid-stimulating immunoglobulin (TSI) is a key autoantibody implicated in Graves' disease pathogenesis.
• Accurate and practical diagnostic tools for TSI are crucial for patient management.

Purpose of the Study:

• To evaluate the clinical utility of a new bioassay for thyroid-stimulating immunoglobulin (TSI).
• To assess the sensitivity and specificity of the TSI bioassay in various thyroid conditions.
• To determine the correlation of TSI levels with disease activity, treatment response, and remission in Graves' disease.

Main Methods:

• A novel, sensitive, and specific bioassay for TSI was employed.
• The bioassay was tested on patients with untreated hyperthyroid Graves' disease, healthy individuals, and patients with other thyroid disorders.
• TSI levels were monitored during and after antithyroid drug therapy and correlated with clinical outcomes.

Main Results:

• The TSI bioassay demonstrated high sensitivity (93%) in untreated hyperthyroid Graves' disease patients.
• The assay showed 100% specificity, with undetectable TSI in healthy subjects and patients with other thyroid conditions.
• TSI levels decreased with therapy and correlated with relapse or remission, with TSI-negative patients remaining in remission post-treatment.

Conclusions:

• The available TSI bioassay is a practical and reliable tool for diagnosing and monitoring Graves' disease.
• TSI levels are valuable indicators of treatment efficacy and predict remission in patients with Graves' disease.
• While TSI correlates with thyroid dysfunction, its correlation with ophthalmopathy is less pronounced. Prenatal TSI may indicate risk for neonatal Graves' disease, though with overlap.